Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3275 |
Name | thymoma |
Definition | A thymus cancer that derives_from epithelial cells located_in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer immune system cancer thymus cancer thymoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 loss | Selinexor | thymoma | predicted - resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01011439 | Phase II | Milciclib | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Terminated | USA | ITA | FRA | 0 |
NCT01025089 | Phase II | Cetuximab Cisplatin + Cyclophosphamide + Doxorubicin | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | Active, not recruiting | USA | 0 |
NCT01301391 | Phase II | Milciclib | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | Terminated | USA | ITA | 0 |
NCT01621568 | Phase II | Sunitinib | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | Completed | USA | 0 |
NCT02220855 | Phase II | Buparlisib | A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas | Completed | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03076554 | Phase II | Avelumab | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | Recruiting | USA | 0 |
NCT03134118 | Phase II | Nivolumab | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM) | Active, not recruiting | NLD | GBR | FRA | ESP | CHE | BEL | 0 |
NCT03193437 | Phase II | Selinexor | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | Terminated | USA | 0 |
NCT03295227 | Phase I | Pembrolizumab | Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma | Recruiting | USA | 0 |
NCT03449173 | Phase II | Sunitinib | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (Style) | Unknown status | ITA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT04417660 | Phase II | Bintrafusp alfa | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | Recruiting | USA | 0 |
NCT04710628 | Phase II | Lenvatinib + Pembrolizumab | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) | Active, not recruiting | ITA | FRA | ESP | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | AUS | 0 |
NCT06248515 | Phase II | Sacituzumab govitecan-hziy | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Recruiting | USA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |